The Orphan Drug Act has been helping sarcoidosis patients receive better treatment options for the last 35 years. Help us ensure its future!
We are thrilled to announce that applications are now being accepted for the 2019-2020 term of the FSR Patient Ambassador Program.
In 2019 the Clinical Studies Network (CSN) will conduct a study focused on cardiac sarcoidosis at all 12 of our sites.
On Oct. 2nd and 3rd FSR’s Executive Director, Ginger Spitzer, was able to travel with PAR to Washington D.C for ATS Hill Day.